Jane Street’s ARS Pharmaceuticals SPRY Stock Holding History

Jane Street’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,400	Closed	-$215K	–	12308
2025 Q3	$215K	Sell	21,400 -21,000	-50%	-$301K	﹤0.01%	9539
2025 Q2	$740K	Buy	42,400 +2,800	+7%	+$40.4K	﹤0.01%	6192
2025 Q1	$498K	Buy	+39,600	New	+$476K	﹤0.01%	6871
2024 Q4	–	Sell	-39,900	Closed	-$579K	–	10519
2024 Q3	$579K	Buy	+39,900	New	+$475K	﹤0.01%	6937
2023 Q3	–	Sell	-12,600	Closed	-$84.4K	–	9341
2023 Q2	$84.4K	Buy	+12,600	New	+$84.1K	﹤0.01%	8069

Other funds holding SPRY

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Tyro Capital Management Miami, Florida $564M AUM 72.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return

Creek Drive Management Group San Francisco, California $368M AUM 23.05% 1-Year Est. Return

Jane Street's SPRY Position: Q3 2026 in Review

Jane Street sold out of ARS Pharmaceuticals (SPRY) in Q3 2026, closing a stake of 17,997 shares — an estimated $105K sold.

Jane Street first reported a position in SPRY in Q4 2020 and held it in 14 quarters. The position peaked at $2.43M in Q3 2025. 133 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

Jane Street reported no remaining ARS Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Jane Street sold 17,997 ARS Pharmaceuticals shares in Q3 2026, an estimated $105K.
Jane Street first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 14 quarters.
Jane Street's ARS Pharmaceuticals position peaked at $2.43M in Q3 2025.
133 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.